Dimerix Says Kidney Disease Trial to Continue After Independent Review; Shares Down 3%
Dimerix Says Kidney Disease Trial to Continue After Independent Review; Shares Down 3%
Dimerix表示，经独立审查后，肾脏疾病试验将继续进行；股价下跌3%
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间